The Pharmacotherapy Council was created in 2018 to address issues about cardiac
pharmacotherapy in the country. This is especially in relation, but not limited to, matters concerning
philhealth, the Philippine National Formulary, and Universal Health Care. The council aims to take the
lead in empowering the PHA membership and the rest of the nation in rational use of cardiac medicine. It
also seeks to give timely updates about pharmacogenetics, pharmacogenomics, and scientific
breakthroughs in cardiac drug development.


“Rational use of medicines requires that patients receive medications appropriate to their clinical
needs, in doses that meet their own individual requirements, for an adequate period of time, and at the lowest cost to them and their community.” (World Health Organization, 1985)

Chair: Maria Concepcion C. Sison, MD
Immediate Past Chair: Richard Henry P. Tiongco II, MD

Esperanza Alcantara I. Cabral
Eric Oliver D. Sison, MD

Dioscoro DC Bayani II, MD
Jezreel L. Taquiso, MD
Jose Eduardo DL Duya, MD
Mylah P. Alfeche
Maria Cristina Joy T. Irorita, MD

Lynn Crisanta R. Panaganiban (Consultant Toxicologist)


No item found!

No Internet Connection